Please read the Patient Information Leaflet (PIL) before taking SOTYKTU® (deucravacitinib).

The psoriasis treatment landscape is complex

You have been prescribed SOTYKTU by your dermatology care team, which means that your previous treatment may not have been working for you.

You can use the interactive diagram below to find out more about the treatments available for psoriasis.

You likely began by talking with your GP about your symptoms.

They will have diagnosed you with psoriasis and discussed treatment options with you. It is likely that they prescribed you a topical therapy to help control your symptoms.

topical therapies

If the topical therapy did not improve your psoriasis
then your GP will have referred you to a specialist.

Specialist Referral

Your specialist will have performed an assessment and discussed the
treatment options below with you.

Please read the Patient Information Leaflet (PIL) before taking SOTYKTU.

References

SOTYKTU UK Patient Information Leaflet (PIL). July 2023. Available at: https://www.medicines.org.uk/emc/product/14871/pil;

SOTYKTU UK Summary of Product Characteristics. August 2024. Available at: https://www.medicines.org.uk/emc/product/14871/smpc#about-medicine;

NICE. Psoriasis: assessment and management. 24 October 2012 [CG153]. Available at:
https://www.nice.org.uk/guidance/cg153/resources/psoriasis-assessment-and-management-pdf-35109629621701 (Accessed April 2025);

NHS. Psoriasis Treatment. Available at https://www.nhs.uk/conditions/psoriasis/treatment/ (Accessed April 2025);

NHS England. What is a biosimilar medicine? February 2023. Available at https://www.england.nhs.uk/long-read/what-is-a-biosimilar-medicine/ (Accessed April 2025).